{
  "id": 16521713,
  "title": "A Win for Durvalumab Doublet in Muscle-Invasive Bladder Cancer",
  "url": "https://urgent.news/2026/10/25/a-win-for-durvalumab-doublet-in-muscle-invasive-bladder-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-25T19:37:39.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/esmo/123570"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- Perioperative treatment with durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin (EV) significantly improved event-free survival (EFS) and overall survival (OS) compared with radical cystectomy in patients with muscle-invasive...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}